Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?

摘要

The rapidly evolving field of treatment for metastatic castration-resistant prostate cancer (mCRPC) and the advent of new drugs that have come to the forefront has brought about the perennial question of what the optimal treatment sequencing strategy is. It is barely a decade since there was hardly any treatment that could be offered to men who progressed to metastatic castration-resistant disease. Despite the initial approval of docetaxel by the US FDA in 2004, administration of chemotherapy was not commonly practiced given the long-held view that chemotherapy for advanced prostate cancer was generally a futile endeavor 101. It was not until further refinement of treatment, better supportive care and development of further hormonal therapies that we began to understand the benefit of providing treatments that each patient is able to use throughout the course of their disease. Inevitably, treatment sequencing has become one of the well-regarded questions, and additional strategies looking at combining therapies may also be appropriate and are discussed herein.